Our view towards HVN is very similar to JBH although there’s been no pop to fresh highs in 2022, it did try to rally in February after delivering its half-year results – EBITDA was down 3.3% while revenue fell 6.2% to $4.91bn. The latest 20c fully franked dividend puts the stock on a forecasted 7.1% yield over the next 12-months, certainly worth watching into weakness as a yield play but a move back towards $4.50 wouldn’t surprise short term.
MM is neutral HVN around $5
Add To Hit List
